A randomized, double‐blind, placebo‐ and positive‐controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects
Authors:
Open Access
- 2 May 2021
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 14 (4) , 1423-1430
Abstract
Durlobactam (formerly ETX2514) is a diazabicyclooctane β‐lactamase inhibitor that inhibits class A, C, and D β‐lactamases. Sulbactam combined with durlobactam has in vitro and in vivo activity against Acinetobacter baumannii including carbapenem‐ and colistin‐resistant isolates and is being developed for treating serious infections due to A. baumannii. The effect of a single supratherapeutic dose of durlobactam on the heart rate corrected QT interval (QTc) was evaluated in healthy subjects in a placebo‐ and active‐controlled, single‐infusion, three‐way crossover study. Subjects were randomized to 1 of 6 sequences that included a single 3‐h i.v. infusion of durlobactam 4 g (supratherapeutic dose), a single 3‐h i.v. infusion of placebo, and a single 3‐h i.v. infusion of placebo plus a single oral dose of moxifloxacin 400 mg given open‐label at the end of the i.v. infusion. In each treatment period, Holter electrocardiogram (ECG) measurements were obtained from predose through 24 h post‐start of infusion. For the primary ECG end point, placebo‐corrected change‐from‐baseline corrected QT Fridericia’s formula (ΔΔQTcF), no significant change was observed with durlobactam. A concentration‐QT analysis demonstrated no significant effect of durlobactam on ECG parameters, including QT interval prolongation. Thus, durlobactam has a low risk for prolonging the QT interval and is unlikely to produce any proarrhythmic effects.Keywords
This publication has 17 references indexed in Scilit:
- Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2018
- Scientific white paper on concentration-QTc modelingJournal of Pharmacokinetics and Pharmacodynamics, 2017
- Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514ACS Infectious Diseases, 2017
- ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumanniiNature Microbiology, 2017
- The Power of Phase I Studies to Detect Clinical Relevant QTc Prolongation: A Resampling Simulation StudyBioMed Research International, 2015
- Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14Drug Safety, 2015
- Antibiotic‐induced Cardiac ArrhythmiasCardiovascular Therapeutics, 2014
- Antimicrobials and the Risk of Torsades de PointesDrug Safety, 2010
- Long-QT SyndromeNew England Journal of Medicine, 2008
- Antimicrobial-Associated QT Interval Prolongation: Pointes of InterestClinical Infectious Diseases, 2006